Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al.
Summary: The randomized trial of tebentafusp for metastatic uveal melanoma showed a higher 1-year overall survival rate among patients who received tebentafusp compared to those who received the investigator's choice of therapy, indicating superior efficacy.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Share Paper
